Pancreatitis News and Research

RSS

Pancreatitis is inflammation of the pancreas. The pancreas is a large gland behind the stomach and close to the duodenum—the first part of the small intestine. The pancreas secretes digestive juices, or enzymes, into the duodenum through a tube called the pancreatic duct. Pancreatic enzymes join with bile—a liquid produced in the liver and stored in the gallbladder—to digest food. The pancreas also releases the hormones insulin and glucagon into the bloodstream. These hormones help the body regulate the glucose it takes from food for energy.

Normally, digestive enzymes secreted by the pancreas do not become active until they reach the small intestine. But when the pancreas is inflamed, the enzymes inside it attack and damage the tissues that produce them.

Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. In severe cases, bleeding, infection, and permanent tissue damage may occur.

Semaglutide as a promising new treatment for alcohol use disorder

Research indicates semaglutide can significantly decrease alcohol consumption and cravings in individuals with comorbid obesity and alcohol use disorder.

4 May 2026

GLP-1 drugs reduce risk of major adverse cardiovascular events

New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes and premature death over a sustained period of time.

30 Apr 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

Higher sugar intake raises gallstone risk in adults, study finds

A cross-sectional NHANES study of 8,975 U.S. adults found that higher total dietary sugar intake was associated with higher odds of gallstones, with each 100 g/day increase linked to a 41% rise after full adjustment. The findings suggest sugar intake may be a modifiable gallstone risk factor, but the study relied on self-reported gallstones and cannot establish causation.

29 Mar 2026

Taking a GLP-1? Doctors say not to forget about movement and mental health

Severe ankle pain drove Jelon Smart to start taking a weight loss injection a year and a half ago.

26 Mar 2026

Updated guideline emphasizes earlier treatment for high cholesterol

The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated guideline for the management of dyslipidemia-abnormal levels of one or more types of lipids or lipoproteins in the blood, including cholesterol and triglycerides.

13 Mar 2026

Experimental therapy eliminates pancreatic precancerous cells in mice study

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors.

12 Mar 2026

Could GLP-1 drugs help curb addiction? Large veteran study points to potential benefit

A large cohort study of more than 600,000 US veterans with type 2 diabetes found that initiating GLP-1 receptor agonists was associated with lower risks of developing substance use disorders compared with SGLT-2 inhibitors. Among veterans with existing substance use disorders, GLP-1 receptor agonist use was also linked to fewer overdose events, hospitalizations, and suicide-related outcomes.

8 Mar 2026

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026

Most statin side effects are not backed by trials

Research indicates that many statin therapy side effects are not supported by evidence, suggesting a need for revised labeling to improve treatment decisions.

9 Feb 2026

Researchers develop blood test to find pancreatic ductal adenocarcinoma

National Institutes of Health (NIH)-supported investigators have developed a blood test to find pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer.

30 Jan 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026

New oral drug safely lowers triglycerides and other blood lipids in Phase 1 trial

In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug can safely lower triglycerides and other blood lipids.

16 Jan 2026

Most Americans still back early hepatitis B vaccination despite policy debate

On December 5, 2025, the Trump administration's Advisory Committee on Immunization Practices (ACIP), whose members were handpicked by Health and Human Services (HHS) Secretary and vaccination critic Robert F. Kennedy Jr., is scheduled to determine whether it should recommend that the Centers for Disease Control and Prevention (CDC) change the recommendation in place since 1991 that newborns be vaccinated against hepatitis B.

5 Dec 2025

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.

20 Nov 2025

New precision therapies reshape the future of pancreatitis treatment

Pancreatitis remains a major global health burden, encompassing acute pancreatitis (AP), chronic pancreatitis (CP), and autoimmune pancreatitis (AIP).

11 Nov 2025

Novel triple receptor agonist shows potent efficacy in lowering high triglycerides

In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients with severe hypertriglyceridemia by more than 60%, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Weight loss drugs used by patients with high triglycerides do not increase pancreatitis risk

In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis or adverse cardiac events.

10 Nov 2025

Triglyceride-lowering drug can also decrease the risk of acute pancreatitis

Researchers from Mass General Brigham have found that olezarsen-a drug designed to lower triglyceride levels-can also decrease the risk of acute pancreatitis, a potential complication in patients with severely elevated triglyceride levels.

10 Nov 2025

GLP-1 drugs calm inflammation beyond diabetes and weight loss

This Journal of Clinical Investigation review describes how glucagon-like peptide-1 (GLP-1)–based medicines reduce systemic and tissue inflammation through both weight-dependent and weight-independent mechanisms. It details preclinical and clinical evidence linking GLP-1 receptor activation to cardiovascular, renal, hepatic, neural, and joint anti-inflammatory effects while outlining uncertainties and future research needs.

4 Nov 2025